TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22884560

Group type: EXPERIMENTAL
Intervention: Ranolazine (500 to 1,000 mg orally twice daily)
Number of subjects: 32
Study: 21047592

Group type: EXPERIMENTAL
Intervention: Prostate specific antigen (PSA) testing
Number of subjects: 3000

Group type: COMPARATOR
Intervention: Standard clinical care
Number of subjects: 3000

Group type: EXPERIMENTAL
Intervention: Active monitoring, radiotherapy, and radical prostatectomy treatments
Number of subjects: 3000
Study: 17573044

Group type: EXPERIMENTAL
Intervention: Active TMS
Number of subjects: 301
Study: 16338192

Group type: EXPERIMENTAL
Intervention: Individualised homeopathic care for 12 weeks
Number of subjects: 169

Group type: COMPARATOR
Intervention: Waiting-list control using self-selected, conventional health care
Number of subjects: 169
Study: 11980329

Group type: COMPARATOR
Intervention: Vancomycin 2 g per day (Group 1, n = 10)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Vancomycin with cefpirome 2 g x 2 (Group 2, n = 10)
Number of subjects: 20
Study: 10077374

Group type: EXPERIMENTAL
Intervention: Perindopril (4 mg) once daily
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg) once daily
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 7562574

Group type: EXPERIMENTAL
Intervention: Single intravenous cocaine doses (0, 8, 16, 32 or 48 mg/70 kg) administered 1 hr after daily methadone
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Repeated intravenous cocaine doses (0, 8 or 32 mg/70 kg) administered 4 times per session at 14‐min intervals
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Higher methadone doses (> 60 mg)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cocaine administration in methadone-maintained individuals
Number of subjects: 16
Study: 2286358

Group type: EXPERIMENTAL
Intervention: CY-VAMP
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: VERCY-VAMP
Number of subjects: 32

Group type: COMPARATOR
Intervention: VAMP alone
Number of subjects: 32
Study: 7396155

Group type: EXPERIMENTAL
Intervention: Alcohol 0.5 mg/kg
Number of subjects: 100

Group type: COMPARATOR
Intervention: 5% dextrose
Number of subjects: 100
Study: 31221782

Group type: EXPERIMENTAL
Intervention: Daratumumab/lenalidomide/dexamethasone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Daratumumab/bortezomib/dexamethasone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (lenalidomide/dexamethasone)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (bortezomib/dexamethasone)
Number of subjects: 0
Study: 31033073

Group type: EXPERIMENTAL
Intervention: Post-surgery (1 year)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Post-surgery (5 years)
Number of subjects: 135

Group type: COMPARATOR
Intervention: No RTW vs. RTW
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Reasons for impaired RTW
Number of subjects: 135
Study: 29078780

Group type: EXPERIMENTAL
Intervention: Apple polyphenol extract (100 mg epicatechin daily for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 25749867

Group type: EXPERIMENTAL
Intervention: NNC0109-0012 administered subcutaneously at various dose levels (0.01-3 mg/kg) as single dose, once weekly, or multiple doses every second week for up to 12 doses.
Number of subjects: 116
Study: 24732962

Group type: EXPERIMENTAL
Intervention: Internet-based writing therapy with therapeutic interaction, 14 sessions
Number of subjects: 34

Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 34
Study: 21362672

Group type: EXPERIMENTAL
Intervention: Intensive hand washing education
Number of subjects: 275
Study: 19779265

Group type: EXPERIMENTAL
Intervention: Endoscopic band ligation (EBL)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Endoscopic hemoclip placement (EHP)
Number of subjects: 34
Study: 17149515

Group type: EXPERIMENTAL
Intervention: At-risk drinking
Number of subjects: 8599

Group type: EXPERIMENTAL
Intervention: Low-risk drinking
Number of subjects: 8599

Group type: EXPERIMENTAL
Intervention: Abstinence
Number of subjects: 8599

Group type: COMPARATOR
Intervention: Tobacco use
Number of subjects: 8599

Group type: COMPARATOR
Intervention: Illicit drug use
Number of subjects: 8599
Study: 16253137

Group type: EXPERIMENTAL
Intervention: Bonus system for hospital doctors
Number of subjects: 2303

Group type: COMPARATOR
Intervention: Weaker incentive bonus system
Number of subjects: 2303

Group type: EXPERIMENTAL
Intervention: Stronger incentive bonus system
Number of subjects: 2303
Study: 11914255

Group type: COMPARATOR
Intervention: Phenylephrine (25 microg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nitroprusside
Number of subjects: 0
Study: 9801901

Group type: EXPERIMENTAL
Intervention: Dacryocystographic examination in leprosy patients
Number of subjects: 2

Group type: COMPARATOR
Intervention: Dacryocystographic examination in non-leprosy patients
Number of subjects: 2
Study: 8552014

Group type: EXPERIMENTAL
Intervention: Bilateral breast pump
Number of subjects: 32

Group type: COMPARATOR
Intervention: Single breast pump
Number of subjects: 32
Study: 2239122

Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine
Number of subjects: 20
Study: 6994924

Group type: EXPERIMENTAL
Intervention: Pulsatile cardiopulmonary bypass
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonpulsatile cardiopulmonary bypass
Number of subjects: 0
Study: 31759809

Group type: EXPERIMENTAL
Intervention: TAU augmented with TCT (n=30)
Number of subjects: 52

Group type: COMPARATOR
Intervention: TAU (n=22)
Number of subjects: 52
Study: 28103159

Group type: EXPERIMENTAL
Intervention: Behavioral sports training (instruction and practice)
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Medication (methylphenidate)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Medication (placebo)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Recreational play
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Sports training (instruction and practice)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Medication (methylphenidate) without sports training
Number of subjects: 73
Study: 27842938

Group type: EXPERIMENTAL
Intervention: Resistance and stretching training program (n = 84)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Control group attending PE classes (n = 46)
Number of subjects: 130
Study: 25891307

Group type: EXPERIMENTAL
Intervention: Individual reminiscence therapy (1 hour/week for 4 weeks)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 78
Study: 24063204

Group type: EXPERIMENTAL
Intervention: Tongguan Capsule (TC)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 18165667

Group type: EXPERIMENTAL
Intervention: CTPA
Number of subjects: 1417

Group type: COMPARATOR
Intervention: V(dot)Q(dot) scanning
Number of subjects: 1417
Study: 14764772

Group type: EXPERIMENTAL
Intervention: Cabergoline treatment for 6 months
Number of subjects: 51
Study: 10800794

Group type: EXPERIMENTAL
Intervention: AAI pacing at 10 beats/min or more above the resting heart rate (Paced)
Number of subjects: 100

Group type: COMPARATOR
Intervention: No atrial pacing (Control)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: AAI pacing (Paced)
Number of subjects: 100
Study: 8620275

Group type: EXPERIMENTAL
Intervention: Meropenem (MP) 1,000 mg every eight hours
Number of subjects: 129

Group type: COMPARATOR
Intervention: Tobramycin 5 mg/kg/day and Clindamycin 900 mg every eight hours (T/C)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Both groups (MP and T/C)
Number of subjects: 129
Study: 1428210

Group type: EXPERIMENTAL
Intervention: Bjork‐Shiley (BS) prosthesis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Starr‐Edwards (SE) prosthesis
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Lillehei‐Kaste (LK) prosthesis
Number of subjects: 150

Group type: COMPARATOR
Intervention: All prostheses (BS, LK, SE)
Number of subjects: 150
Study: 4008075

Group type: EXPERIMENTAL
Intervention: monomethoxy polyethylene glycol‐coupled HBV (PEG‐HBV)
Number of subjects: 24

Group type: COMPARATOR
Intervention: honey bee venom (HBV)
Number of subjects: 24
Study: 29165000

Group type: EXPERIMENTAL
Intervention: Building Better Caregivers (BBC) intervention
Number of subjects: 83
Study: 25863600

Group type: EXPERIMENTAL
Intervention: Defusion
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Reappraisal
Number of subjects: 73

Group type: COMPARATOR
Intervention: Suppression
Number of subjects: 73
Study: 23438314

Group type: EXPERIMENTAL
Intervention: COMPASS followed by face-to-face (FF) coaching sessions
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: COMPASS followed by web-based (WEB) coaching sessions
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo control (PBO) group
Number of subjects: 49
Study: 20946286

Group type: EXPERIMENTAL
Intervention: Standard electrocardiography (ECG) at first evaluation and follow-up
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Age, presence of paroxysmal atrial flutter or fibrillation, number of CTG repeats
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Female sex
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Lower left ventricular ejection fraction
Number of subjects: 70
Study: 19793390

Group type: EXPERIMENTAL
Intervention: Usual care plus Depression Care for People with Lung Cancer
Number of subjects: 200

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 200
Study: 18200773

Group type: EXPERIMENTAL
Intervention: Controlled-release nifedipine added once daily to ARB
Number of subjects: 0

Group type: COMPARATOR
Intervention: Increasing ARB dosage
Number of subjects: 0
Study: 15210257

Group type: EXPERIMENTAL
Intervention: Implementation of personal health records (PHRs) by case managers (CMs) in one half of the patients.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Cohort without personal health records (PHRs).
Number of subjects: 150
Study: 11190754

Group type: EXPERIMENTAL
Intervention: Budesonide 280 micrograms once daily
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Budesonide 140 micrograms once daily
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Budesonide (all doses)
Number of subjects: 157

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 157
Study: 9355432

Group type: EXPERIMENTAL
Intervention: Lidocaine 2.5% ointment
Number of subjects: 8
Study: 8408738

Group type: EXPERIMENTAL
Intervention: Propranolol (20 mg)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg)
Number of subjects: 13
Study: 3534900

Group type: EXPERIMENTAL
Intervention: Clonidine (single-dose)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine (two-week trial)
Number of subjects: 12
Study: 29856286

Group type: EXPERIMENTAL
Intervention: Hypnotherapy (5 to 7 sessions over 8 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional psychiatric treatment (control group)
Number of subjects: 0
Study: 27327616

Group type: EXPERIMENTAL
Intervention: Two injections of MVA (MM group)
Number of subjects: 120

Group type: COMPARATOR
Intervention: One injection of Placebo and one injection of MVA (PM group)
Number of subjects: 120
Study: 25842580

Group type: EXPERIMENTAL
Intervention: Bispectral Index monitoring
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard sedation with Ramsay score 5-6 without Bispectral Index monitoring
Number of subjects: 50
Study: 22691240

Group type: EXPERIMENTAL
Intervention: Automated telephone reminders
Number of subjects: 6903

Group type: EXPERIMENTAL
Intervention: Measurement strategies requiring a second dispensing event
Number of subjects: 6903

Group type: EXPERIMENTAL
Intervention: Measurement strategies that do not require a dispensing event
Number of subjects: 6903
Study: 20385666

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide adsorber included in the CPB circuit
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control group (without adsorber)
Number of subjects: 17
Study: 18926073

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation guided by respiratory physiology, thrice a day, 15 minutes each time for 8 weeks.
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pulmonary rehabilitation with pursed lip respiration, thrice a day, 15 minutes each time for 8 weeks.
Number of subjects: 60

Group type: COMPARATOR
Intervention: No pulmonary rehabilitation.
Number of subjects: 60
Study: 16526176

Group type: EXPERIMENTAL
Intervention: Day hospital
Number of subjects: 238

Group type: COMPARATOR
Intervention: Inpatient ward
Number of subjects: 238

Group type: EXPERIMENTAL
Intervention: Both settings
Number of subjects: 238
Study: 12714433

Group type: EXPERIMENTAL
Intervention: Isoflavones (biochanin or formononetin, 80 mg/d)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Isoflavones (formononetin)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 10479203

Group type: EXPERIMENTAL
Intervention: Increased physical activity in men
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Increased physical activity in women
Number of subjects: 210

Group type: COMPARATOR
Intervention: Postmenopausal status
Number of subjects: 210

Group type: COMPARATOR
Intervention: Estrogen use
Number of subjects: 210
Study: 8743188

Group type: EXPERIMENTAL
Intervention: Moderate 30 min cycle ergometer exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Short‐term maximal exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Moderate exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Anaerobic exercise
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Maximal exercise
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 15
Study: 1713709

Group type: EXPERIMENTAL
Intervention: MK-329 (10 mg orally)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 6351619

Group type: EXPERIMENTAL
Intervention: Oral tinidazole, 500 mg twice daily for 5 days
Number of subjects: 30

Group type: COMPARATOR
Intervention: Oral placebo with vaginal cream (with or without sulfonamides)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Vaginal sulfonamide cream with oral placebo
Number of subjects: 30
Study: 29025878

Group type: EXPERIMENTAL
Intervention: GLP-1 receptor antagonist exendin 9-39 (Ex9-39)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 26542498

Group type: EXPERIMENTAL
Intervention: Automated system of personalized educational reminders sent to patients and family physicians, mailed at 1, 2, 5, 8, and 11 months after discharge.
Number of subjects: 852

Group type: EXPERIMENTAL
Intervention: Automated system of personalized educational reminders
Number of subjects: 852

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 852
Study: 25951693

Group type: EXPERIMENTAL
Intervention: High school physiology education
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Females
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: Second-year students studying physiology
Number of subjects: 1083

Group type: EXPERIMENTAL
Intervention: General knowledge of physiology
Number of subjects: 1083
Study: 22622049

Group type: EXPERIMENTAL
Intervention: 2 doses of MCV4
Number of subjects: 324

Group type: COMPARATOR
Intervention: 1 dose of MCV4
Number of subjects: 324

Group type: EXPERIMENTAL
Intervention: 2 doses of MCV4 in subjects with CD4% <15
Number of subjects: 324
Study: 19417618

Group type: EXPERIMENTAL
Intervention: 600 mg oral rifampin once daily for 7 days
Number of subjects: 12
Study: 17332210

Group type: EXPERIMENTAL
Intervention: Virtual group (home asthma telemonitoring with store-and-forward technology)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Both groups (office-based and virtual)
Number of subjects: 120
Study: 15382436

Group type: EXPERIMENTAL
Intervention: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 12 months
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Endovesical treatment with Bacillus Calmette Guerin (BCG) for 6 months
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (no BCG treatment)
Number of subjects: 90
Study: 11590992

Group type: EXPERIMENTAL
Intervention: Lispro insulin
Number of subjects: 85
Study: 9881512

Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Sucralfate
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 16
Study: 7921059

Group type: EXPERIMENTAL
Intervention: Laparoscopic cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open cholecystectomy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Extracorporeal shockwave lithotripsy (ESWL)
Number of subjects: 0
Study: 3293891

Group type: EXPERIMENTAL
Intervention: Non-meat protein supplement
Number of subjects: 64

Group type: COMPARATOR
Intervention: Meat protein supplement
Number of subjects: 64
Study: 30318944

Group type: EXPERIMENTAL
Intervention: Magnesium exposure
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Antibiotic exposure
Number of subjects: 1747

Group type: EXPERIMENTAL
Intervention: Increasing gestational age (GA) at delivery
Number of subjects: 1747

Group type: COMPARATOR
Intervention: Control group (infants that did not develop CP)
Number of subjects: 1747
Study: 30392115

Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg/day; 3 weeks on/1 week off) plus fulvestrant (500 mg)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo plus fulvestrant (500 mg)
Number of subjects: 35
Study: 28537501

Group type: EXPERIMENTAL
Intervention: Tapentadol prolonged release (PR)
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Oxycodone controlled release (CR)
Number of subjects: 990

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 990

Group type: EXPERIMENTAL
Intervention: Tapentadol PR
Number of subjects: 990
Study: 25856791

Group type: EXPERIMENTAL
Intervention: Integrated Care (IC)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 155
Study: 23046099

Group type: EXPERIMENTAL
Intervention: House dust mite inhalation
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22031874

Group type: EXPERIMENTAL
Intervention: Real tDCS (anodal over left DLPFC, cathodal over right supraorbital region)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 13
Study: 19463380

Group type: EXPERIMENTAL
Intervention: Aspirin resistant patients (ARU >= 550)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Aspirin sensitive patients
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Clopidogrel low-responders (platelet inhibition <19%)
Number of subjects: 209

Group type: COMPARATOR
Intervention: Clopidogrel responders
Number of subjects: 209
Study: 16556246

Group type: EXPERIMENTAL
Intervention: Preventive treatment for headaches
Number of subjects: 176
Study: 14606081

Group type: EXPERIMENTAL
Intervention: Ultrasonography
Number of subjects: 225

Group type: COMPARATOR
Intervention: Serology
Number of subjects: 225
Study: 11349487

Group type: EXPERIMENTAL
Intervention: Cleft lip patients (n=20)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (40 healthy subjects)
Number of subjects: 42
Study: 8792789

Group type: EXPERIMENTAL
Intervention: Outlier practitioners identified based on performance evaluation.
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Performance evaluation across cases seen by a given physician.
Number of subjects: 430

Group type: EXPERIMENTAL
Intervention: Performance correlation between guidelines.
Number of subjects: 430
Study: 1363631

Group type: EXPERIMENTAL
Intervention: MAST‐CLA
Number of subjects: 195
Study: 6476868

Group type: EXPERIMENTAL
Intervention: banked breast milk
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: preterm formula
Number of subjects: 194

Group type: COMPARATOR
Intervention: maternal milk supplemented with banked breast milk
Number of subjects: 194
Study: 3537092

Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Combination of Theophylline and Albuterol
Number of subjects: 18
Study: 30241150

Group type: EXPERIMENTAL
Intervention: Gemcitabine 1,000 mg/m2
Number of subjects: 70

Group type: COMPARATOR
Intervention: Bleomycin 15 IU/m2 and Vincristine 1.4 mg/m2
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Both Gemcitabine and BV
Number of subjects: 70
Study: 26818604

Group type: EXPERIMENTAL
Intervention: Hummus alone (2.7 g, 10.8 g, 25 g avCHO)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Hummus plus white bread (2.7 g, 5.4 g, 10.8 g avCHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: White bread (25 g avCHO)
Number of subjects: 10

Group type: COMPARATOR
Intervention: White bread (50 g avCHO)
Number of subjects: 10
Study: 24745810

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (maintaining hemoglobin 10.0 g/dL > hemoglobin ≧ 8.0 g/dL)
Number of subjects: 186

Group type: COMPARATOR
Intervention: Liberal transfusion strategy (maintaining hemoglobin ≧ 10.0 g/dL)
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy
Number of subjects: 186

Group type: COMPARATOR
Intervention: Liberal transfusion strategy
Number of subjects: 186
Study: 23479138

Group type: EXPERIMENTAL
Intervention: Telemedicine (n = 9)
Number of subjects: 20

Group type: COMPARATOR
Intervention: In-person care (n = 11)
Number of subjects: 20
Study: 20855178

Group type: EXPERIMENTAL
Intervention: Nonarticulated pneumatic postamputation mobility aid (PPAMA)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Articulated amputee mobility aid (AMA)
Number of subjects: 29
Study: 19265756

Group type: EXPERIMENTAL
Intervention: Sony PlayStation II EyeToy
Number of subjects: 56
Study: 16842396

Group type: EXPERIMENTAL
Intervention: Solifenacin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Solifenacin and warfarin or digoxin
Number of subjects: 0
Study: 12491520

Group type: EXPERIMENTAL
Intervention: Peptides/IFA with GM-CSF (250 microm subcutaneously daily for 5 days)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Peptides/IFA alone
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 48
Study: 10850937

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) at doses of 0.075 IU/kg, 0.150 IU/kg, and 0.300 IU/kg for 5 postoperative days
Number of subjects: 104

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 104
Study: 8673754

Group type: EXPERIMENTAL
Intervention: Lacidipine 4 mg once daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 1818790

Group type: EXPERIMENTAL
Intervention: Captopril (41 +/- 3 mg in three divided doses)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Enalapril (8 +/- 1 mg once daily)
Number of subjects: 33